Press Release

5001 Spring Valley Road
Suite 500W
Dallas, TX 75244
+1 855.696.6100

Vivione Biosciences Announces Successful Completion of Its Early-Stage Pilot Study at the Cleveland Clinic

 

DALLAS, TX--(Marketwired - December 16, 2014) - Vivione Biosciences Inc. ("Vivione") (TSX VENTURE: VBI) is pleased to announce the successful completion of its early stage pilot study at the Cleveland Clinic focused on applying its RAPID-B bacterial detection platform to the primary screening of suspected urinary tract infections (UTIs).

"While our primary goal was to gather substantial data on clinical samples for later modification of the system's software algorithms, it was clearly evident from the first day forward we could accurately detect clinically defined UTIs at the time the sample arrived in the lab, in essence 18-24 hours faster than traditional methods," said Chief Medical Officer, Dr. Matthew Gombrich. "Our next phase will expand on the 100% sensitivity seen in this evaluation to determine the clinical specificity of the system in a larger clinical context," Gombrich continued.

"This is once again proof that RAPID-B has a place not only in the Food Safety sector, as was demonstrated by our AOAC approvals, but in the clinical realm as well. We're thrilled by these preliminary results and look forward to expanding the data for regulatory approval and commercializing the product for rapid, high sensitivity bacterial screening in the clinical setting. NIH estimates there are over 500,000 hospital-associated UTIs annually and we feel the RAPID-B system will offer an excellent means to both diagnose and lower costs associated with the disease," said Kevin Kuykendall, CEO of Vivione Biosciences.

The Vivione's RAPID-B platform, which is currently commercialized in both the Food Safety and the Oil and Gas sectors, is a highly sensitive and rapid platform for detecting bacteria in complex matrices (like beef or frac water). Vivione is currently applying the system not only to urinary tract infection screening but blood infections and meningitis screening as well. Vivione has also recently filed IP focused around rapid antibiotic susceptibility determination using the RAPID-B platform.

About Vivione

Vivione is a TSX Venture Exchange listed biosciences company focused on the commercialization of its proprietary RAPID-B platform; an integrated platform of hardware, software and reagents that quickly and accurately identify, quantify and qualify bacteria and other pathogens in key food & water safety, clinical, industrial and oil & gas environments. For more information, visit www.VivioneBiosciences.com.

Cautionary Statements

This news release contains "forward-looking statements" within the meaning of applicable securities laws. Although Vivione believes that the expectations reflected in its forward-looking statements are reasonable, such statements have been based on factors and assumptions concerning future events that may prove to be inaccurate. These factors and assumptions are based upon currently available information to Vivione. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. This news release contains forward-looking information relating to the commercialization and the development of the RAPID-B system, Vivione's business and growth strategy. Readers are cautioned to not place undue reliance on forward-looking statements. The statements in this news release are made as of the date of this news release and, except as required by applicable law, Vivione does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. Vivione undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Vivione, or its financial or operating results or (as applicable), their securities.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Contact Information

Contact:
Mika Bradford
Vivione Biosciences
(817) 705-7221
mbradford@vivionebiosciences.com

5001 Spring Valley Road
Suite 500W
Dallas, TX 75244
+1 855.696.6100

Disclosure

Please read the terms and conditions section of this website carefully before using the Vivione Biosciences Inc. (the “Company”) web site. By accessing or using this site, you agree to the terms and conditions as set out in the terms and conditions section of this web site. You should review the terms and conditions section regularly as it may change at any time at our sole discretion. If you do not agree to any term or condition, you should not access or otherwise use this site.

General information regarding the Company set forth on the following pages of this website, including management's assessment of the Company's future plans and operations contains forward looking statements that involve substantial known and unknown risks and uncertainties. Wherever possible, words such as "may", ''would", "could", "should", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "aim", "endeavour" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs based on its experience and expertise with respect to future events and are based on information currently available to management. Management uses forward-looking statements because it believes they provide useful information with respect to the Company, and cautions readers that the information may not be appropriate for other purposes and should not be read as guarantees of future performance or results.

Forward looking statements are subject to numerous risks and uncertainties, some of which are beyond the management and the Company’s control, including but not limited to, the impact of general economic conditions, industry conditions, fluctuation of foreign exchange rates, imperfection of estimates, industry competition, availability of qualified personnel and management, stock market volatility, timely and cost effective access to sufficient capital from internal and external sources, ability to integrate and realize anticipated benefits from acquisitions, ability to resell third party network communications at favorable rates, and to effectively manage growth. The Company's actual results, performance or achievement could differ materially from those expressed in or implied by, these forward looking statements and accordingly, no assurance can be given that any of the events anticipated to occur or transpire from the forward looking statements will provide any benefits to the Company. All data presented herein should be read in conjunction with the Company's regulatory filings with the appropriate securities regulatory authorities and the System for Electronic Document Analysis and Retrieval (“SEDAR”). Copies of these filings are available for review under the Company's SEDAR profile at www.sedar.com.